ftInvstr

GUFICBIO · Healthcare ₹480.95 +10.23% Mkt Cap ₹4806 Cr overvalued

GUFICBIO

Healthcare Drug Manufacturers - Specialty & Generic

★ Watchlist ⧉ Add to bucket

₹480.95

+10.23% today · 30d +17.97%

as of 2026-11-09

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for GUFICBIO. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-06-30

REVENUE

₹261 Cr

+16.58% YoY

NET PROFIT

₹22 Cr

+70.71% YoY

OPM

18.01%

+2.78pp YoY

EPS

₹2.22

PE 63.85

Intrinsic value · DCF ₹61.20 · Margin of safety -87.3% (overvalued) · FCF yield 0.29%

◇ Sector Position

PEERPEROCE %

GUFICBIO63.8513.0

SUNPHARMA37.7921.44

DIVISLAB93.121.56

ZYDUSLIFE28.424.22

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance STRONG 90

Valuation STRETCHED 20

Growth STEADY 55

Profitability DECENT 68

Technicals NEUTRAL 60

Risk LOW 90

Key Stats

TTM PE

63.85

P/B

7.05

52W HIGH

₹480.95

OFF HIGH

0.0%

DIV YIELD

0.02%

MKT CAP

₹4806 Cr

◉ Active Signals

MACDBullish6.4941

RSI(14)Bearish71.62

Near 52W HighBullish0.0

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold GUFICBIO and at what entry.